Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X about a recent paper by Gabriel Hortobagyi et al. published in Annals of Oncology:
“Final iDFS results from NATALEE, previously presented at SABCS23, are now published in Annals of Oncology, showing a 3% delta in 3-year iDFS.
Things move fast, though: updated data were presented at ESMO24, with the delta rising to 5% at 4 years.”
Authors: Gabriel Hortobagyi, A. Lacko, J. Sohn, A. Chakravartty, D. Slamon et al..
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023